Renal angiomyolipomas (AMLs) are benign renal masses that are often asymptomatic and detected incidentally.
However, treatment might be necessary in symptomatic presentations or when the mass exceeds 4 cm in size. While the goal of management for renal AMLs is to relieve symptoms and prevent hemorrhage, a priority is renal function preservation, especially given the propensity of these lesions to recur. The traditional treatment for renal AMLs is renal angioembolization or surgical excision of the lesion. With advancements in minimally invasive surgery, several other modalities have now emerged for nephron sparing approaches. These include angioembolization, laparoscopic and percutaneous ablative therapies such as radiofrequency ablation, cryoablation and microwave ablation, and pure or robot-assisted laparoscopic partial nephrectomy. Given the relatively low frequency of renal AMLs requiring treatment, much of the available literature on these minimally invasive approaches is largely extrapolative, based on series on small renal masses, i.e. renal cell carcinoma (RCC). This report is based on a thorough review of the published literature to date on the minimally invasive treatment and outcomes of renal AMLs.
Written by:
Sivalingam S, Nakada SY. Are you the author?
University of Wisconsin-Madison, Madison, WI, USA.
Reference: Curr Urol Rep. 2013 Apr;14(2):147-53.
doi: 10.1007/s11934-013-0311-3
PubMed Abstract
PMID: 23378161
UroToday.com Adrenal and Kidney Conditions Section
